Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (NASDAQ: ANGO) reported its fiscal Q1 2021 results with net sales of $70.2 million, a 6.3% increase year-over-year. The company faced challenges from COVID-19, particularly in its Oncology segment, where net sales dropped 12.3% to $12.3 million. The Vascular Access segment saw strong growth of 21.4%, totaling $28.1 million. Gross margin declined to 50.9%, down 700 basis points year-over-year. A net loss of $4.3 million was reported, or $0.11 per share. Guidance for fiscal 2021 projects net sales between $278 million and $284 million.